Mitsubishi Tanabe Pharma Canada Announces That Treatment For Amyotrophic Lateral Sclerosis (ALS) Has Been Added to British Columbia Pharmacare Formulary Français

News provided by

Mitsubishi Tanabe Pharma Canada, Inc.

Aug 19, 2020, 09:00 ET

TORONTO, Aug. 19, 2020 /CNW/ - Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), is now listed on the British Columbia (BC) PharmaCare Formulary (special authorization).

Continue Reading
RADICAVA Bag Product Shot (CNW Group/Mitsubishi Tanabe Pharma Canada, Inc.)
RADICAVA Bag Product Shot (CNW Group/Mitsubishi Tanabe Pharma Canada, Inc.)
RADICAVA Product Box (CNW Group/Mitsubishi Tanabe Pharma Canada, Inc.)
RADICAVA Product Box (CNW Group/Mitsubishi Tanabe Pharma Canada, Inc.)
RADICAVA Manufacturing
RADICAVA Manufacturing

"ALS is a rapidly progressive, neurodegenerative and fatal disease, and the listing of this therapy is an encouraging step for the ALS community," said Atsushi Fujimoto, President, MTP-CA. "We are very grateful to the Government of B.C. for providing access to eligible patients under its provincial PharmaCare Formulary."

In addition to the BC PharmaCare Formulary (special authorization), RADICAVA also is listed on the following:

  • Régie de l'assurance maladie du Québec (RAMQ) formulary (special authorization)
  • Ontario Drug Benefit Formulary (Exceptional Access Program)
  • Alberta Drug Benefit List (special authorization)
  • New Brunswick Drug Plan (NBDP) formulary (special authorization)
  • Manitoba Drug Benefits and Interchangeability Formulary (special authorization)
  • Saskatchewan Formulary (special authorization)
  • Nova Scotia Drug Formulary (special authorization)

MTP-CA continues to have discussions with other provinces, territories and federal agencies regarding the listing of RADICAVA under additional publicly funded drug programs.

About RADICAVA® (edaravone)
RADICAVA (edaravone) is indicated to slow the loss of function in patients with amyotrophic lateral sclerosis (ALS), as measured by the ALS Functional Rating Scale - Revised (ALSFRSR).1 Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) through an iterative clinical development platform over a 13-year period. In 2015, edaravone was approved for use as a treatment for ALS in Japan and South Korea. RADICAVA was approved by the U.S. Food and Drug Administration in May of 2017. Marketing authorization was granted in Canada in October 2018 and Switzerland in January 2019.

About Mitsubishi Tanabe Pharma Canada, Inc.
Based in Toronto, Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) with a goal to provide therapies for some of the most difficult-to-treat diseases, including ALS. For more information, please visit www.mt-pharma-ca.com.

About Mitsubishi Tanabe Pharma America, Inc.
Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTPA is dedicated to delivering innovative products that address the unmet medical needs of patients in North America. It was established by MTPC to commercialize approved pharmaceutical products in North America. For more information, please visit www.mt-pharma-america.com.

1

RADICAVA® (edaravone) Canada Product Monograph. October 2019. https://www.mt-pharma-ca.com/our-product/

SOURCE Mitsubishi Tanabe Pharma Canada, Inc.

Media inquiries: Debbie Etchison, 908-340-8578, [email protected]

Organization Profile

Mitsubishi Tanabe Pharma Canada, Inc.